Cimzia
EMA expands label for UCB’s Cimzia in axial spondyloarthritis
August 5, 2020Research and Development, Sales and Marketing Cimzia, EMA, Europe
The European Medicines Agency has expanded the existing approval of UCB’s Cimzia (certolizumab pegol) to cover the treatment of axial …
New Phase 3 data confirms safety and efficacy of UCB’s Cimzia in plaque and psoriatic arthritis
April 30, 2019Manufacturing and Production, Research and Development Cimzia, UCB Pharma, pharma, plaque psoriasis, psoriasis
New Phase 3 data has been released by UCB Pharma on the safety of Cimzia (certolizumab pegol) in the treatment …
NICE recommends UCB’s Cimzia in severe plaque psoriasis
April 18, 2019Sales and Marketing Cimzia, NICE, UCB Pharma, UK, pharma, plaque psoriasis, psoriasis
NICE has announced its decision to recommend UCB Pharma’s Cimzia (certolizumab pegol) for use on the NHS in England in …
NICE approves Cimzia but blocks Ilumetri in treatment of psoriasis
December 4, 2018Manufacturing and Production, Sales and Marketing Almirall, Cimzia, Ilumetri, NICE, UCB, UK, pharma, psoriasis
UK drug watchdog NICE has announced two new recommendations relating to medicines for the treatment of psoriasis, approving UCB Pharma’s …
EMA approves Cimzia for use in treating plaque psoriasis
July 2, 2018Sales and Marketing Cimzia, EMA, UCB, indication, pharmaceutical
The Brussels-based pharmaceutical company UCB has announced that the European Medicines Agency (EMA) has approved a label extension for Cimzia …
UCB’s Cimzia secures first-of-its-kind FDA approval in plaque psoriasis
May 29, 2018Manufacturing and Production, Sales and Marketing Cimzia, FDA, UCB, US, pharma, psoriasis
The FDA has expanded the label for UCB’s Cimzia (certolizumab pegol) in the US, approving the therapy for the treatment …
Nice backs UCB’s Cimzia as alternate therapy for severe rheumatoid arthritis
July 13, 2016Research and Development, Sales and Marketing Cimzia, NICE, UCB, regulation, rheumatoid arthritis
The National Institute for Health and Care Excellence (Nice) has recommended UCB Pharma’s Cimzia (certolizumab pegol) on its own or …
New UCB chief starts and expands team
January 13, 2015Sales and Marketing Cimzia, Jean-Christophe Tellier, Neupro, UCB, roch deliveux, vimpat
New UCB chief executive Jean-Christophe Tellier who succeeded Roch Doliveux this year has also welcomed three new members to the …
Biotech industry failed by UK, says UCB
February 27, 2014Research and Development, Sales and Marketing Cimzia, NHS, UCB, biotech, doliveux, tellier, vimpat
The UK biotechnology industry has ‘missed the boat’ and not fulfilled its potential, according to outgoing UCB chief executive Roch …
Cimzia results excite UCB in psoriatic arthritis
February 16, 2012Research and Development, Sales and Marketing Cimzia, UCB, psoriatic arthritis
UCB will submit Cimzia for psoriatic arthritis by the end of 2012, after positive Phase III trial results for the …
UCB plans €250m plant to meet Cimzia demand
December 29, 2010Manufacturing and Production Cimzia, Switzerland, UCB, pharma manufacturing
Belgian biotechnology company UCB has started construction of a new microbial manufacturing facility in Bulle, Switzerland to help meet demand …
Patient access scheme secures NICE approval for Cimzia
January 22, 2010Sales and Marketing Cimzia, NICE, UCB, rheumatoid arthritis
UCB Pharma’s Cimzia has been recommended by NICE to treat rheumatoid arthritis – but only if a patient access scheme …
Latest content
FibroFind appoints Lee Borthwick as CEO
